BioInfect 2014 Successfully Addresses the Anti-Microbial Agenda
This year’s BioInfect conference, organised by Bionow, was a major success. Exploring the global anti-microbial agenda, BioInfect looked at new innovations currently in progress to tackle the increasing problem. The one day conference, which addressed the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, took place at the Alderley Park Conference Centre, Cheshire on the 4 November 2014.
The conference brought together scientists, policy makers and government officials who convened to set the anti-microbial agenda. There were three main sessions presented at the conference entitled: “Progress: National and International Perspectives”, “Animal Health — the issues” and “Commercial Models.” In addition, there was a company technology showcase presenting leading innovation and development in this area.
Technology showcased at BioInfect included the latest innovations from companies from the north of the UK. These included the development of a wide range of early stage, proprietary therapeutics moving away from a broad spectrum approach to more focused methodologies more akin to the targeted approach now being taken with cancer. In addition, there was particular focus on the development of innovative therapies employing nanopolymer drug delivery technology, and taking biologic and vaccine approaches to developing treatments to meet the high unmet medical need.
BioInfect explored other research into technological tools for health workers to diagnose, manage, monitor and track emerging infections and drug resistance, as well as discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system.
Dr Geoff Davison, CEO of Bionow, commented: “We are very pleased with the attendance, engagement and feedback received and that the key areas which can move this agenda forward were discussed. BioInfect brings together professionals from the life sciences industry, universities, NHS, government and policy making bodies and allows them to explore the areas which can truly address this problem for mankind. In order to tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way by open and coordinated discussion and planning to ensure that we have a health care system that can sustainably control and treat infections.”
Related News
-
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News CPHI Frankfurt 2022: Innovator Interviews – Bioiberica
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We caught up with Mónica Gómez Navarro (Marketing Manager Branded Ingredients), ... -
News CPHI Frankfurt 2022: Innovator Interview – Procaps Group
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We interviewed Rosella Del Vecchio Herrera, Marketing Director at Procaps Group, to discover h... -
News From the floor - CPHI Frankfurt 2022
The live blog from the people on the ground at CPHI Frankfurt - covering all stand-out news, memorable moments, and keynote updates from the 2022 event. -
News How to Commercialise an Advanced Therapy: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Andrea Zobel, Senior Director, Personalized Supply Chain at World Courier (Berlin Germany), Melissa Lattanzi, VP Emerging Therapies at AmerisourceBergen (King of Prussia, USA), and Hans-Peter Scherzer, Customer Suc... -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance